{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:54:43Z","timestamp":1793397283075,"version":"4.5.0"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,6,27]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Acanthamoeba<\/jats:italic>\n                      keratitis is a rare, severe corneal infection. Until the recent approval of polihexanide (PHMB) 0.08% by the European Medicines Agency, there were no licensed medical therapies and current treatments relied on off-label or compounded products. The purpose of this study is to estimate the relative efficacy of PHMB 0.08% compared with current treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A patient-level indirect treatment comparison (ITC) compared data from a pivotal trial of PHMB 0.08% and a retrospective real-world study of current treatments: (1) any anti-amoebic treatment (AAT), (2) PHMB 0.02% plus a diamidine (propamidine or hexamidine) 0.1% and (3) chlorhexidine (CXL) 0.02% alone or in combination with a diamidine. The primary outcome was the clinical resolution rate (CRR) without surgery within 12 months. ITCs were implemented using propensity scoring analysis with overlap weighting and adjustment for covariates (age, sex, disease stage, treatment delay, prior use of corticosteroid or antiviral).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The CRR was 84.8% for PHMB 0.08% (n=66), 43.6% for any AAT (n=227), 55.0% for PHMB 0.02% plus a diamidine (n=111) and 40.0% for CXL 0.02% with or without a diamidine (n=35). In the unweighted analysis, the absolute difference (95% CI) in favour of PHMB 0.08% was 41.2% (28.8%, 51.2%; p&lt;0.001) compared with any AAT, 29.9% (14.5%, 42.1%; p&lt;0.001) compared with PHMB 0.02% plus a diamidine and 44.8% (23.9%, 62.3%; p&lt;0.001) compared with CXL 0.02% with or without a diamidine. Similar results were observed in the weighted analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that PHMB 0.08% when delivered with the recommended protocol is significantly more effective than currently used treatments in achieving clinical resolution without surgery. The study limitations include differences in recruitment periods, diagnostic criteria and drug delivery methodology, as well as limitations of the ITC adjustment measures which can lead to residual confounding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2024-002082","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T03:35:14Z","timestamp":1752464114000},"page":"e002082","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Polihexanide (PHMB) 0.08% versus currently used treatments for\n                    <i>Acanthamoeba<\/i>\n                    keratitis: indirect treatment comparisons"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03274895","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-6059","authenticated-orcid":false,"given":"Vincenzo","family":"Papa","sequence":"first","affiliation":[{"name":"Medical Affairs, SIFI, Aci Sant'Antonio (Catania), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Galeone","sequence":"additional","affiliation":[{"name":"University of Milan-Bicocca Faculty of Statistical Science, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Francesco","sequence":"additional","affiliation":[{"name":"HEOR Value Hub, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle H","family":"Bodicoat","sequence":"additional","affiliation":[{"name":"HEOR Value Hub, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Alves","sequence":"additional","affiliation":[{"name":"HEOR Value Hub, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Spaepen","sequence":"additional","affiliation":[{"name":"HEOR Value Hub, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K G","family":"Dart","sequence":"additional","affiliation":[{"name":"Corneal & External isease, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Ocular Biology & Therapeutics, UCL Institute of Ophthalmology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Arteaga","sequence":"additional","affiliation":[{"name":"HEOR Value Hub, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"2026010721210272000_10.1.e002082.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2022.04.003"},{"key":"2026010721210272000_10.1.e002082.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314485"},{"key":"2026010721210272000_10.1.e002082.3","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31820f7763"},{"key":"2026010721210272000_10.1.e002082.4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ophtha.2023.09.031","article-title":"The Orphan Drug for Acanthamoeba Keratitis (ODAK) Trial: PHMB 0.08% (Polihexanide) and Placebo versus PHMB 0.02% and Propamidine 0.1","volume":"131","author":"Dart","year":"2024","journal-title":"Ophthalmology"},{"key":"2026010721210272000_10.1.e002082.5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222092","article-title":"The rising incidence of Acanthamoeba keratitis: A 7-year nationwide survey and clinical assessment of risk factors and functional outcomes","volume":"14","author":"Randag","year":"2019","journal-title":"PLoS One"},{"key":"2026010721210272000_10.1.e002082.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2022.101372","article-title":"Risk factors, management, and outcomes of Acanthamoeba keratitis: A retrospective analysis of 110 cases","volume":"25","author":"Scruggs","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2026010721210272000_10.1.e002082.7","unstructured":"Faria R , Alava MH , Manca A , et al . NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data. Sheffield, UK: NICE Decision Support Unit, 2015."},{"key":"2026010721210272000_10.1.e002082.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29245\/2572-9411\/2023\/2.1208","article-title":"Current Clinical Evidence for Agents used in Acanthamoeba Keratitis: Systematic Literature Reviews","volume":"8","author":"H. Bodicoat","year":"2023","journal-title":"J Rare Dis Res Treat"},{"key":"2026010721210272000_10.1.e002082.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.06.010"},{"key":"2026010721210272000_10.1.e002082.10","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-310806"},{"key":"2026010721210272000_10.1.e002082.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.01.031"},{"key":"2026010721210272000_10.1.e002082.12","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.5.536"},{"key":"2026010721210272000_10.1.e002082.13","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2020.1846753"},{"key":"2026010721210272000_10.1.e002082.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.10.018"},{"key":"2026010721210272000_10.1.e002082.15","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.85.7.842"},{"key":"2026010721210272000_10.1.e002082.16","first-page":"1","article-title":"The Mycotic Ulcer Treatment Trial: A Randomized Trial Comparing Natamycin vs Voriconazole","volume":"10","author":"Prajna","year":"2012","journal-title":"Archives of Ophthalmology Dec"},{"key":"2026010721210272000_10.1.e002082.17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/ICO.0000000000001781","article-title":"Management Algorithm for Fungal Keratitis: The TST (Topical, Systemic, and Targeted Therapy) Protocol","volume":"38","author":"Sharma","year":"2019","journal-title":"Cornea"},{"key":"2026010721210272000_10.1.e002082.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.08.040"},{"key":"2026010721210272000_10.1.e002082.19","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113775","article-title":"Effectiveness and Safety of Topical Chlorhexidine and Vitamin E TPGS in the Treatment of Acanthamoeba Keratitis: A Survey on 29 Cases","volume":"9","author":"Caruso","year":"2020","journal-title":"J Clin Med"},{"key":"2026010721210272000_10.1.e002082.20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/2008-322X.163782","article-title":"Chlorhexidine monotherapy with adjunctive topical corticosteroids for acanthamoeba keratitis","volume":"10","author":"Sefidan","year":"2015","journal-title":"J Ophthalmic Vis Res"},{"key":"2026010721210272000_10.1.e002082.21","doi-asserted-by":"publisher","DOI":"10.1177\/11206721241299470"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2024-002082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:21:53Z","timestamp":1767849713000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2024-002082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,13]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjophth-2024-002082"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2024-002082","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}